Member Info for Fadec92

RMM Sareum said in previous RNS that the preferred route of SRRA is on-Licensing, is that the same as non-diluted partner, or info Tim and John know different!

It’s good news guys but it dosnt impact on Sareum business going forward, the SRA737/LDG with a PD-L1 is very good news too with respectable data and that should be enough, but until we get some good substantial news from SRRA taking SRA737 forward without their “we want to progress really we do but in our own time, when we are ready” unfortunately!

On what grounds would there be a breach of contract between SRRA and ICR/SAR, with a reduction in development money for SRA737, which i think is the PARP combo as the trial was not started could that be deamed a trigger of breach, how did Sierra word it, think they said research and production costs?

This is a bizarre update, would normally be a tweet!

Ha ha Stoney not smarter just we all know different information so can respond here! ATB!

A private company Esperas Pharma have a Chk1 in phase 1/2 trials as pointed out by Quotedata and SRRA!

Hi Stoney this is an immune checkpoint inhibitor, a PD-L1 a different class of Cancer Therapy and Immunotherapy, the class or field of inhibition that Chk1 is in is the DNA Damage Response Checkpoint Inhibitors, which are synthetic produced molecules!

Imfinzi is Durvalumab!

https://en.m.wikipedia.org/wiki/Durvalumab

Thanks Stoney so getting new patents and splitting them is advantageous and they are trying to achieve as per what was said to the attendees at the AGM!

Hi Thoth did they say in the AGM that US Patents for SDC 1801 - SDC 1802 are not necessarily needed to interest companies in the products, we know that there is a master print of compounds that are protected and granted from 2013 for compounds for inhibitors of kinases and in particular FLT3, FLT4 and Aurora kinases?

Thanks Thoth, they have to disclose it in this way I see! :/)

That would only get you 27.5% of the milestones and a percentage of royalty’s of SRA737 and I don’t think that you would be able to buy (ICR, CPF)!

I agree RMM the 10-K is very positive as in the progression of SRA737 with PARP inhibitors and the preclinical research showing rationale of pairing the two together as are two different aspects of DDR inhibition and the potential synergy can exist, also mentions Wee1, I get that information of the reduction in trial and manufacturing cost to facilitate the lead candidate in that it specifically mentions a reduction in trial cost of $5m of SRA737 so this is probably the cost of the PARP and SRA737 as it is in preclinical and the information of the trial that Thoth posted, plus I would have thought a percentage of the other reductions between SRA737/SRA141 manufacturing costs, and a $2.1 million decrease in research fees, so call it an $8m reduction, it’s not a big some of money for a partner like Gilead to pick up to progress, and all the terminology presented by Sierra suggests that they are very happy with SRA737 and are going to progress it that’s the bit for me is that they are very willing to do so and the is looking to be progressing as a lead molecule in the synthetic DDR field and a molecule that would be desirable to partner!

So are now progressing this?

“To our knowledge, Eli Lilly and Company is developing prexasertib, an intravenous Chk1/Chk2 inhibitor in several clinical settings, the most advanced of which are in Phase 2 clinical trials. There are also preclinical programs focused on developing Chk1 inhibitors. If SRA737 is approved, it will compete with existing therapies and currently marketed drugs for the indication or indications for which it is approved.“

Seams free to move up here, maybe a run!

On number 3 it’s Immune Checkpoint Inhibitors are also called Checkpoint inhibitors it’s about PD-L1, number 4 is about chemotherapy and synthetic small molecules ie PARP/Chk1/Wee1/ATR!

“T Cell Checkpoint Inhibitors. In a similar way that CD47 on cancer cells suppresses macrophages, some cancer cells can suppress T cell attacks by expressing immune checkpoint proteins such as PD-L1. This can reduce the potency of the specific anti-cancer T cell responses that macrophages mobilize after ingesting cancer cells. Combining our magrolimab immunotherapy with T cell checkpoint inhibitors may help maximize the T cell response induced by macrophages.”

Sorry Potnak can’t see anything on that page was looking at it earlier!

Thanks Fax should be ok, keep the faith! ATB!

Potnak is there info that it could enhance chk1 think I’ve missed something here, Thankyou?

There never is a direct correlation to the answer with surmising/postulating looking at research and looking at the company’s that matter what they are trying to achieve, trying to figure out what the hell is going on, only they know or the academics until Sierra actually comes out tells us directly and says they are advancing SRA737 then at that point only can we be happy, what ever they are doing is certainly taking a fair bit of time, last June to be looking for undillutive alliances, whether it’s Gilead and trying to keep everything in house as not to loose a cut a big slice out of the 737 pie!

So is SRA737/LDG creating a similar environment that the CD47 inhibitor would be doing to pair with a PD-L1/CTLA-4, or is it a mechanism that can be synergies, or another armament in the toolbox to kill cancer?

“activate more Macrophages could be a rationale!”

change to :-

“activate the increased population Macrophages could be a rationale!”